Sonder Holdings Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
The lawsuit claims that during the class period, the Defendants made materially false and/or misleading statements, as well as failed to disclose the following: (a) QuidelOrtho oversold COVID-19 tests to its distributors and pharmacy chain customers beyond their capacity to resell to healthcare providers and end users; (b) this led to excessive inventories of COVID-19 tests throughout the supply chain; (c) consequently, QuidelOrtho’s distributors and pharmacy chain customers were likely to significantly decrease their orders for COVID-19 tests; (d) undisclosed issues were likely to delay the U.S. commercial launch of QuidelOrtho’s new test, the Savanna Respiratory Viral Panel-4 Test; (e) due to these factors, the Defendants did not have a reasonable basis for their optimistic statements regarding QuidelOrtho’s business, financial conditions, and growth prospects.
